Business Wire

ZOLL Propaq M Selected by U.S. Air Force and U.S. Army as Their Deployable Vital Signs Monitor

Del

ZOLL® Medical Corporation, an Asahi Kasei Group Company that manufactures medical devices and related software solutions, announced today the receipt of a sole source contract from the Defense Logistics Agency to supply Propaq® M deployable vital signs monitors to the U.S. Air Force and the U.S. Army.

The Propaq M, selected as the joint “Product of Choice,” is an advanced vital signs transport monitor, with capabilities far beyond the Propaq Encore 206, which has been the tried and trusted vital signs monitor serving the U.S. military over the last 25 years.

The Propaq M was designed specifically for the rigors of military operations in the most austere environments. The Propaq M can be equipped with an integrated defibrillator and pacer for critical lifesaving mission readiness. This configuration, known as the Propaq MD, eliminates the need to carry a separate monitor and defibrillator to improve operational efficiencies. During the competitive evaluation period, military subject matter experts stressed the importance of printing the 12 Lead ECG report and related patient data directly from the vital signs monitor. The Propaq M is the only airworthy vital signs monitor that is available with an integrated printer, thereby allowing the services to reduce size, weight and cube by eliminating the need to carry a separate standalone printer.

“We are very pleased to see the continued commitment to the ZOLL Propaq platform,” said A. Ernest Whiton, President of ZOLL’s global Resuscitation division. “This recent award demonstrates the DoD’s confidence in ZOLL’s monitoring and monitoring/defibrillation technology that is currently deployed throughout the services today.”

The Propaq M now joins several other ZOLL airworthy products selected by the services as their standard critical care transport medical device, further enhancing Defense Healthcare’s goal for interoperability throughout all roles of care in the U.S. Navy, the U.S. Air Force, the U.S. Marine Corps, and the U.S. Army from Medevac to strategic critical care airlift missions worldwide.

The Propaq M is equipped with the complete advanced Masimo® rainbow® SET® technology, including total hemoglobin (SpHb®) and pleth variability index (PVI®) along with advanced physiologic monitoring with three integrated invasive blood pressure channels. The Propaq M offers robust data communication and remote viewing capabilities. This remote viewing capability, currently installed on the USNS Comfort and USNS Mercy, has been instrumental in recent humanitarian missions to the Caribbean, Central America, and Asia Pacific regions of the world.

The Propaq M now joins several other ZOLL airworthy products selected by the services as their standard critical care transport medical devices including:

  • The Propaq MD ultra-lightweight, airworthy monitor/defibrillator that provides advanced monitoring capabilities, including full Masimo® Rainbow® SET technology and data transmission capabilities
  • The EMV+® 731 Series portable transport ventilator designed specifically for the U.S. military
  • The 330 Aspirator, the next generation in “smart” airworthy aspirators
  • The SMEED™ critical care platform designed to secure ZOLL monitors, monitor defibrillators, ventilators, and aspirators to standard NATO litters.

About ZOLL Medical Corporation
ZOLL Medical Corporation, an Asahi Kasei Group Company, develops and markets medical devices and software solutions that help advance emergency care and save lives, while increasing clinical and operational efficiencies. With products for defibrillation and monitoring, circulation and CPR feedback, data management, therapeutic temperature management, and ventilation, ZOLL provides a comprehensive set of technologies that help clinicians, EMS and fire professionals, and lay rescuers treat victims needing resuscitation and acute critical care. For more information, visit www.zoll.com.

About Asahi Kasei
The Asahi Kasei Group is a diversified group of companies led by holding company Asahi Kasei Corp., with operations in the material, homes, and health care business sectors. Its health care operations include devices and systems for acute critical care, dialysis, therapeutic apheresis, transfusion, and manufacture of biotherapeutics, as well as pharmaceuticals and diagnostic reagents. With more than 30,000 employees around the world, the Asahi Kasei Group serves customers in more than 100 countries. For more information, visit www.asahi-kasei.co.jp/asahi/en/.

©2018 ZOLL Medical Corporation. All rights reserved. EMV+, SMEED, and ZOLL are trademarks or registered trademarks of ZOLL Medical Corporation in the United States and/or other countries. Asahi Kasei is a registered trademark of Asahi Kasei Corporation. Propaq is a registered trademark of Welch Allyn. Masimo, PVI, rainbow, SET, and SpHb are trademarks or registered trademarks of Masimo Corporation. All other trademarks are the property of their respective owners.

Contact information

ZOLL Medical Corporation
Diane Egan, +1-978-421-9637
degan@zoll.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

ERYTECH Announces Filing of 2017 “Document de Référence” and 2017 Annual Report on Form 20-F24.4.2018 20:30Pressemelding

Regulatory News: ERYTECH Pharma (Euronext Paris: ERYP – Nasdaq: ERYP), the clinical-stage biopharmaceutical company developing innovative therapies for severe forms of cancer and orphan diseases based on its proprietary ERYCAPS platform, encapsulating therapeutic drug substances inside red blood cells, today announced that it had filed its 2017 “Document de Référence” for the year ended December 31, 2017, including the management report and the annual financial report with the “Autorité des Marchés Financiers (AMF)” and its Annual Report on Form 20-F for the year ended December 31, 2017 with the U.S. Securities and Exchange Commission (SEC). These documents can be accessed on the Investors section of the Company’s corporate website (www.erytech.com). In addition, the “Document de Référence” is also available on the AMF’s website (http://www.amf-france.org) and the Annual Report on Form 20-F is also available on the SEC’s website (www.sec.gov). Printed copies of these documents are also

Rimini Street Launches New Solutions that Further Extend the Life and Value of Enterprise Software as a Foundation for Innovation24.4.2018 16:00Pressemelding

Rimini Street, Inc . (Nasdaq: RMNI), a global provider of enterprise software products and services, and the leading third-party support provider for Oracle and SAP software products, today announced the first offerings in a family of solutions designed to provide improved competitive advantage to organizations with mature and valuable enterprise software investments that can be used as a foundation for innovation. Rimini Street’s new solutions can enable an organization to quickly and cost-effectively modernize their current enterprise software with the latest desired features and capabilities, future-proof their technical platforms against yet-unknown technology changes, and secure their systems against a constantly evolving threat environment. Rimini Street’s new solutions enable organizations to leverage their existing systems as a solid foundation for an innovative hybrid IT strategy. This press release features multimedia. View the full release here: https://www.businesswire.com/

Novaliq to Present Scientific and Clinical Research During the 2018 Association for Research in Vision and Ophthalmology Meeting in Honolulu, HI24.4.2018 15:53Pressemelding

Novaliq GmbH, a specialty pharmaceutical company with a disruptive drug delivery platform that transforms poorly soluble drugs into effective therapeutics for ophthalmology, today announced that four scientific posters will be presented at the 2018 Association for Research in Vision and Ophthalmology (ARVO) Meeting in Honolulu, HI (April 29-May 3). The variety of data to be presented reflects Novaliq’s dedication to science and clinical research. With the collection of posters, Novaliq will share clinical and pre-clinical data on its EyeSol® drug delivery technology and provide insights into the mode of action of its NOV03/NovaTears® water-free therapy for the treatment of dry eye disease (DED). Furthermore, Novaliq will present its first pre-clinical efficacy data in glaucoma. Scientific posters supported by Novaliq will include: “Influence of perfluorohexyloctane containing eye drops on tear film thickness in patients with mild to moderate dry eye disease.” Authors: Garhöfer G., Schm

Temasys Communications and Appian Partner to Power Real-Time Communications in the Contact Center24.4.2018 15:00Pressemelding

Temasys Communications announced today that Appian has integrated with the Temasys Skylink technology, enabling real-time communications, including chat and co-browsing, in Appian’s new Intelligent Contact Center (ICC) Platform. “For our contact center customers, omni-channel communications are essential. Appian is working with Temasys to provide contact centers with real-time communication channels such as chat and co-browsing via the Temasys versatile SDKs,” said Arturo Oliver, Senior Director of Product Strategy at Appian. Temasys Skylink APIs will be compatible with the Appian Intelligent Contact Center Platform, making it easy for Appian customers to add real-time communication to their applications, including chat, voice, video and co-browsing. These integrations enable users to visit a website, begin a chat session that seamlessly escalates to a voice call and extend to co-browsing — all without changing apps or establishing a new connection. “We’re thrilled to work with Appian

PPG Reports Sustainability Progress, New 2025 Goals24.4.2018 13:07Pressemelding

PPG (NYSE:PPG) today released its 2017 Corporate Sustainability Report, which details the company’s continued progress in strengthening its sustainable operations in 2017 and the launch of new, aggressive sustainability goals it aims to achieve by 2025. The report is available at sustainability.ppg.com. “PPG’s sustainability efforts go beyond product innovations to extend to our customers’ operations and the communities in which we operate,” said Mark Cancilla, PPG vice president, environment, health and safety. “We are encouraged by our progress in 2017 and excited about our new goals, which are representative of the challenges and opportunities of our current business portfolio.” The company achieved the following progress in 2017: 32 percent of sales from products that provide customers with a sustainable advantage, an increase of 60 percent since 2012. This includes the unveiling of multiple products that provide a sustainable solution, such as Sigma Air Pure, a revolutionary bio-b

Bioiberica Approves Its Combined Drug for Osteoarthritis in Five More European Countries24.4.2018 12:17Pressemelding

Bioiberica's combination of chondroitin sulphate and glucosamine hydrochloride, a slow action drug to treat osteoarthritis symptoms, was approved as an ethical drug in France, Austria, Hungary, Poland, and Finland through a mutual recognition process from Spain. ‘This approval confirms that Drug Agencies from different countries attest to the effectiveness and safety of the combination of pharmaceutical grade chondroitin sulphate and glucosamine hydrochloride. This drug has proven to reduce pain and improve mobility in people affected by knee osteoarthritis which, due to its safety profile, could also be used as an alternative by those patients with cardiovascular or gastrointestinal problems who should not be prescribed anti-inflammatory drugs chronically’, stated Dr Juan Gispert, Bioiberica's R&D director. The principle study that guarantees its effectiveness is the MOVES clinical trial, published in the Annals of the Rheumatic Diseases, which concludes that the combination of chondr